-
Audentes Therapeutics Expands Treatment Candidates for Duchenne MD
Audentes Therapeutics is expanding its pipeline of potential therapies, expecting to address 80% of patients with Duchenne muscular dystrophy (DMD). Learn more about this story here.
What are your thoughts on this expansion? Will it impact you?
Sorry, there were no replies found.
Log in to reply.